No­vo Nordisk tem­pers ex­pec­ta­tions for hefty M&A deals as di­a­betes, obe­si­ty sales soar

As No­vo Nordisk counts a surge in sales, thanks in large part to its obe­si­ty and di­a­betes fran­chis­es, the Dan­ish drug­mak­er has its check­book out for deals. Just don’t hold your breath for any big M&A moves.

For the first nine months of 2023, No­vo Nordisk re­port­ed DKK 166.398 bil­lion (more than $26 bil­lion) in net sales, a 29% growth com­pared to the same pe­ri­od last year. Obe­si­ty care, in par­tic­u­lar, grew by 167% to DKK 30.4 bil­lion — con­tribut­ing to over­all growth in di­a­betes and obe­si­ty care of 36% to DKK 153.8 bil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER